Abstract
The early phase of acute myocardial ischemia is associated with an elevated risk of ventricular reentrant arrhythmias. Indeed, after partial or total occlusion of a coronary artery, some regions of the heart experience a reduction in myocardial blood flow. This causes metabolic and cellular processes, such as hypoxia, hyperkalemia and acidosis, which lead to changes in the transmembrane ionic dynamics. The effect of such alterations may result in the formation of electrical loops and reentries.
Computational models could simulate the generation of arrhythmias, possibly persistent, in condition of ectopic beats and in presence of acute myocardial regions. Since quantitative information (extent, localization, …) about acute ischemic regions are hardly available from clinics, to date, computational models only integrate imaging data from chronic infarcted ventricles. This may not accurately reflect the acute condition.
This work presents a novel patient-specific electrophysiological model, based on images of myocardial blood flow maps acquired during a pharmacologically induced acute ischemic event. The model personalization is obtained with the partitioning of the left ventricle geometries on the basis of the myocardial blood flow maps. First, we aim to numerically investigate the induction and sustainment of reentrant drivers in patient-specific scenarios, in order to assess their arrhythmic propensity. Secondly, we perform an intra-patient sensitivity analysis, where different levels of acute ischemia are virtually depicted for the most arrhythmogenic patient. Our results suggest that the amount of ischemic regions seems to have less influence on arrhythmogenesis than their pattern.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Italian Ministry of Health within the PNC PROGETTO HUB LIFE SCIENCE - DIAGNOSTICA AVANZATA (HLS-DA) INNOVA, PNC-E3-2022-23683266-CUP: D43C22004930001, within the Piano Nazionale Complementare Ecosistema Innovativo della Salute - Codice univoco investimento: PNC-E3-2022-23683266.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Review Board approval was obtained (R250/15-CCM 262). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
alessandra.corda{at}polimi.it
stefano.pagani{at}polimi.it
christian.vergara{at}polimi.it
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
